Benlysta Reviews: Learn the amazing truth on how it works [Updated]

 

Picture shows how Benlysta works by interfering with B cell proliferation
How Benlysta works: it decreases the activation of autoreactive B-cells that make bad autoantibodies such as ANA and anti-DNA 

The pink guys are lymphocytes (T-cells in this case) under electron microscopy. photo from Texas Center for Cancer Nanomedicine

 

Benlysta (belimumab) Decreases the Cells that Make Bad Antinuclear Antibodies: See Benlysta Reviews Below

 

Read this and other Benlysta reviews to learn how amazing Benlysta works. There are very good reasons why it has achieved 3 FDA approvals for lupus (systemic lupus erythematosus or SLE, pediatric lupus, and lupus nephritis) in the past 10 years. It is safe and effective per many Benlysta reviews. It is used as an IV treatment for lupus as well as a self-injectable form. Before you get your Benlysta first infusion or self-injection, make sure to learn as much as you can from this and other Benlysta reviews. Today, we use Benlysta for lupus nephritis, SLE, and pediatric lupus. 

How the target (BLyS) of Benlysta normally works in the immune system:

 

BLyS is B-cell fertilizer

There is an immune system chemical messenger (a cytokine) called BLyS (B Lymphocyte Stimulator) also called BAFF (B cell activating factor). B-cells that make antibodies require this BLyS (BAFF) to stay alive.

For Example: Suppose you get pneumonia from a bacteria called Pneumococcus pneumoniae (pneumococcus). B-cells are called upon to produce pneumococcal antibodies. The immune system makes a lot of BLyS to keep the pneumococcal antibody producing B-cells alive. When the infection is gone, the immune system stop making BLyS. The B-cells then retire and die because we don’t need them any more. When cells of the body retire and die a natural death when not needed, it is called apoptosis. Think of BLyS as “B-cell fertilizer.” Without BLyS, B-cells go through apoptosis, which is an important process of the body so that younger, newer cells can replace old, unneeded cells.

Cytokines, like BLyS and BAFF, in lupus patients and lymphocytes
If the pink dots in this picture is BLyS, then how Benlysta works is by attaching to this BLyS floating around. Less BLyS means that bad, autoreactive B-cells can go into retirement (apoptosis).

 

The tiny pink things floating around are cytokines (like BLyS) ready to attach to the purple white blood cell and tell it what to do (stay alive in the case of antibody producing B-cells) photo credit: Wikipedia and Scientific Animations at https://commons.wikimedia.org/wiki/File:Cytokine_release.jpg

Benlysta (belimumab) attaches to BLyS and takes it away so B-cells can die ​

Lupus patients constantly make too much BLyS, so those bad B-cells that make autoantibodies that attack your own body’s cells (ANA, anti-dsDNA, etc) stay alive, and can even be immortal. Benlysta binds to BLyS and takes it away. The bad B-cells can then retire, die, and go away (go through apoptosis).

Benlysta is too large of a molecule to be taken by pill form. The stomach and intestines would just destroy it and absorb just parts of it. Therefore, it is a self-injectable and an IV treatment for lupus instead. If you are reading this before your Benlysta first infusion or injection, that is wonderful! But, make sure to learn more by reading other Benlysta reviews as well. 

Yet, during infections, the immune system can still make lots of BLyS so that the important, needed B-cells can fight off the infection.

After studying Benlysta patients for over 20 years, we are not seeing any more infections in our Benlysta patients than we do in those taking placebo plus “standard of care” therapies.

Think of Benlysta as balancing out the immune system, achieving homeostasis, rather than suppressing it.

COMMENT above:

Are you on Benlysta? How are you doing on it?

 

Author

Don Thomas, MD, author of “The Lupus Encyclopedia” and “The Lupus Secrets

Reference:

Shin, W., Lee, H.T., Lim, H. et al. BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus. Nat Commun 9, 1200 (2018). https://doi.org/10.1038/s41467-018-03620-2

Disclosure: I am on the Speaker’s Bureau of GSK, the manufacturer of Benlysta

Leave a Reply

Your email address will not be published. Required fields are marked *